Billiontoone (NASDAQ:BLLN) Stock Price Up 3.2% – What’s Next?

Billiontoone, Inc. (NASDAQ:BLLN) shares rose 3.2% during trading on Friday . The stock traded as high as $89.99 and last traded at $89.09. Approximately 45,845 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 207,081 shares. The stock had previously closed at $86.34.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BLLN shares. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a research report on Saturday, November 15th. Stifel Nicolaus started coverage on Billiontoone in a research report on Monday, December 1st. They set a “buy” rating and a $145.00 price target on the stock. Zacks Research upgraded shares of Billiontoone to a “hold” rating in a research note on Tuesday, December 2nd. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Billiontoone in a research note on Wednesday, December 10th. Finally, Piper Sandler reissued an “overweight” rating on shares of Billiontoone in a report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Billiontoone currently has a consensus rating of “Moderate Buy” and an average price target of $137.83.

Billiontoone Stock Performance

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.06). The business had revenue of $83.52 million during the quarter, compared to analysts’ expectations of $82.86 million.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.